Cambridge Trust’s CRISPR Therapeutics CRSP Stock Holding History

Cambridge Trust’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	$102K	Hold	1,500	–	–	﹤0.01%	340
2023 Q4	$93.9K	Hold	1,500	–	–	﹤0.01%	346
2023 Q3	$68.1K	Hold	1,500	–	–	﹤0.01%	387
2023 Q2	$84.2K	Hold	1,500	–	–	﹤0.01%	373
2023 Q1	$67.8K	Hold	1,500	–	–	﹤0.01%	408
2022 Q4	$61K	Hold	1,500	–	–	﹤0.01%	430
2022 Q3	$98K	Hold	1,500	–	–	﹤0.01%	366
2022 Q2	$91K	Hold	1,500	–	–	﹤0.01%	406
2022 Q1	$94K	Hold	1,500	–	–	﹤0.01%	432
2021 Q4	$114K	Buy	+1,500	New	+$131K	﹤0.01%	405

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cambridge Trust's CRSP Position: Q1 2024 in Review

Cambridge Trust held its CRISPR Therapeutics (CRSP) position steady in Q1 2024 at 1,500 shares worth $102K. The position accounts for ﹤0.01% of the portfolio, ranked #340.

Cambridge Trust first reported a position in CRSP in Q4 2021 and has held it in 10 quarters since. The position peaked at $114K in Q4 2021. 484 funds tracked by Wall St. Rank hold CRSP as of Q1 2024.

Cambridge Trust held 1,500 shares of CRISPR Therapeutics worth $102K as of Q1 2024.
Cambridge Trust left its CRISPR Therapeutics share count unchanged in Q1 2024.
CRISPR Therapeutics made up ﹤0.01% of Cambridge Trust's portfolio in Q1 2024, its #340 holding.
Cambridge Trust first reported a position in CRISPR Therapeutics in Q4 2021 and has held it in 10 quarters since.
Cambridge Trust's CRISPR Therapeutics position peaked at $114K in Q4 2021.
484 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2024.

Based on Cambridge Trust's 13F filing for Q1 2024, filed 30 May 2024.